Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0974 for acute migraine in patients with stable vascular disease
2007-007723-40Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telcagepant in migraine (3 arms), sponsored by Merck & Co. Primary endpoint: Pain freedom at 2 hours postdose (first attack, first period). Started Jan 2008; status: completed.
02
Drugs
telcagepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2007-007723-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007723-40.